Skip to main content
. 2017 Jan 3;3(1):e000371. doi: 10.1136/rmdopen-2016-000371

Figure 4.

Figure 4

(A) ORs comparing safety outcomes and (B) mean differences in patient-reported outcome endpoints in patients treated with triple therapy versus TNFi–methotrexate in patients who had inadequate response to methotrexate at 6 months. AE, adverse event; CrI, credible interval; FEM, fixed-effects model; HAQ-DI, Health Assessment Questionnaire-Disability Index; PGA, patient general assessment; REM, random-effects model; TNFi, tumour necrosis factor inhibitor.